QT
TPTX

Quantamental Technologies’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Quantamental Technologies’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,548
Closed -$265K – 591
2021
Q4 		$265K Buy
5,548
+1,673
+43% +$74.8K 0.13% 276
2021
Q3 		$257K Buy
3,875
+193
+5% +$13.7K 0.17% 208
2021
Q2 		$287K Buy
+3,682
New +$272K 0.25% 162

Other funds holding TPTX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Quantamental Technologies's TPTX Position: Q1 2022 in Review

Quantamental Technologies sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 5,548 shares — an estimated $265K sold.

Quantamental Technologies first reported a position in TPTX in Q2 2021 and held it in 3 quarters. The position peaked at $287K in Q2 2021. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

  • Quantamental Technologies reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Quantamental Technologies sold 5,548 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $265K.
  • Quantamental Technologies first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Quantamental Technologies's Turning Point Therapeutics, Inc. Common Stock position peaked at $287K in Q2 2021.
  • 155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Quantamental Technologies's 13F filing for Q1 2022, filed 16 May 2022.